| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
25032 |
| Drug |
Pembrolizumab |
| Brand |
Keytruda® |
| Indication |
Pembrolizumab (Keytruda®) in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy. |
| Rapid review commissioned |
24/04/2025 |
| Rapid review completed |
21/05/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
11/06/2025 |
